India, July 1 -- The U.S. Food and Drug Administration (FDA) has authorized Philip Morris International to market its Zyn nicotine pouches as a lower-risk alternative to cigarettes, marking a significant milestone for the fast-growing smokeless nicotine category.
The FDA said 20 Zyn nicotine pouch variants can now be marketed with the claim that "using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."
The agency concluded that the available scientific evidence supports the claim and that the products could significantly reduce harm and the risk of tobacco-related disease for adult smokers who switch completely from cigarettes.
The decision follows y...